192 related articles for article (PubMed ID: 8629676)
1. Long-term intraperitoneal deferoxamine for hemochromatosis.
Swartz RD; Legault DJ
Am J Med; 1996 Mar; 100(3):308-12. PubMed ID: 8629676
[TBL] [Abstract][Full Text] [Related]
2. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
Kobayashi M; Yano K; Fujisawa S
Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
[TBL] [Abstract][Full Text] [Related]
3. Neonatal hemochromatosis: failure of deferoxamine therapy.
Jonas MM; Kaweblum YA; Fojaco R
J Pediatr Gastroenterol Nutr; 1987; 6(6):984-8. PubMed ID: 3681586
[TBL] [Abstract][Full Text] [Related]
4. Management of iron overload with a disposable multi-day delivery system.
Paolo C; Francesco S; Sergio A
Am J Hematol; 1996 Jan; 51(1):95. PubMed ID: 8571948
[No Abstract] [Full Text] [Related]
5. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T; Ferro G; Frontini V; Percolla S
Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
[TBL] [Abstract][Full Text] [Related]
6. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload.
Nelson SC; Hennessy JM; McDonough EA; Guck KL
J Pediatr Hematol Oncol; 2006 Mar; 28(3):182-5. PubMed ID: 16679946
[TBL] [Abstract][Full Text] [Related]
7. Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I.
Smithson WA; Perrault J
Mayo Clin Proc; 1982 May; 57(5):322-5. PubMed ID: 7078263
[TBL] [Abstract][Full Text] [Related]
8. [Hemochromatotic cirrhosis complicating pyridoxine-sensitive hereditary sideroblastic anemia. Case report].
Abadia R; Rochant H; Levy VG
Ann Med Interne (Paris); 1983; 134(4):327-32. PubMed ID: 6614712
[TBL] [Abstract][Full Text] [Related]
9. Type 3 hemochromatosis and beta-thalassemia trait.
Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
[TBL] [Abstract][Full Text] [Related]
10. [Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
Baudouy P; Lombrail P; Azancot I; Piekarski A; Martin E; Slama R
Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1240-6. PubMed ID: 6418103
[TBL] [Abstract][Full Text] [Related]
11. Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.
Blume KG; Beutler E; Chillar RK; Fahey JL; Sharkoff D; Zia PK
JAMA; 1978 May; 239(20):2149-51. PubMed ID: 642157
[TBL] [Abstract][Full Text] [Related]
12. Treatment of iron overload.
Cohen A; Witzleben C; Schwartz E
Semin Liver Dis; 1984 Aug; 4(3):228-38. PubMed ID: 6091277
[No Abstract] [Full Text] [Related]
13. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
Bene C; Manzler A; Bene D; Kranias G
Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
[TBL] [Abstract][Full Text] [Related]
14. [-Cardiomyopathy as the cause of death in genetic hemochromatosis-].
von Herbay A; Niederau C; Pilichowska M; Reinecke P; Perings C; Vester E; Strohmeyer G; Häussinger D
Z Gastroenterol; 1996 Mar; 34(3):178-82. PubMed ID: 8650971
[TBL] [Abstract][Full Text] [Related]
15. Four-hour measurement of urinary iron excretion after deferoxine treatment: a rapid, simple method for study of iron excretion.
Bonkovsky HL; Weber R; Aaron L
Am J Gastroenterol; 1990 May; 85(5):554-7. PubMed ID: 2337058
[TBL] [Abstract][Full Text] [Related]
16. [Present aspects of the treatment of hemochromatosis (apropos of 100 observations)].
Darnis F; Mossé A; Breauté C; Delorme ML
Ann Med Interne (Paris); 1971 Dec; 122(12):1193-210. PubMed ID: 5151624
[No Abstract] [Full Text] [Related]
17. [Treatment and prevention of chronic iron overload (author's transl)].
Brissot P; Bourel M; Simon M
Gastroenterol Clin Biol; 1981 Dec; 5(12):1108-19. PubMed ID: 7319207
[No Abstract] [Full Text] [Related]
18. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
Osborne RH; De Abreu Lourenço R; Dalton A; Houltram J; Dowton D; Joshua DE; Lindeman R; Ho PJ
Value Health; 2007; 10(6):451-6. PubMed ID: 17970927
[TBL] [Abstract][Full Text] [Related]
19. [Temporary blindness in hemochromatosis].
Sakić D; Zlatar P
Ophthalmologica; 1974; 168(4):253-60. PubMed ID: 4837176
[No Abstract] [Full Text] [Related]
20. Reversible severe hereditary hemochromatotic cardiomyopathy.
Madani TA; Bormanis J
Can J Cardiol; 1997 Apr; 13(4):391-4. PubMed ID: 9141972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
